# A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers

> **NCT01855048** · PHASE1 · COMPLETED · sponsor: **Intron Biotechnology, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteers
- Anti-Bacterial Agents
- Methicillin-Resistant Staphylococcus Aureus

## Interventions

- **BIOLOGICAL:** N-Rephasin® SAL200
- **OTHER:** INT200-Placebo

## Key facts

- **NCT ID:** NCT01855048
- **Lead sponsor:** Intron Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-06
- **Primary completion:** 2014-02-07
- **Final completion:** 2014-02-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01855048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01855048, "A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01855048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*